Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gilead Sciences is currently recruiting participants for a global, multicenter Phase 3 study titled ‘A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)’. The study aims to compare the efficacy of sacituzumab govitecan, a promising drug, against the standard of care in improving objective response rates and overall survival in patients with ES-SCLC.
The intervention being tested is sacituzumab govitecan, administered intravenously. It is designed to target and treat extensive stage small cell lung cancer, providing a potential new option for patients who have undergone previous treatments.
This interventional study employs a randomized, parallel assignment model with no masking, focusing on treatment as its primary purpose. Participants are divided into two groups: one receiving sacituzumab govitecan and the other receiving standard treatments like Topotecan or Amrubicin (in Japan only).
The study began on April 4, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 4, 2025, indicating ongoing recruitment and study progress.
For investors, this study could signal significant market implications for Gilead Sciences. Positive outcomes may enhance the company’s stock performance and investor sentiment, especially given the competitive landscape of cancer treatments. Keeping an eye on updates from this study could provide valuable insights into Gilead’s future market position.
The study is ongoing, with further details available on the ClinicalTrials portal.